Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3- 2B12) in nude mice bearing peritoneal carcinomatosis

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1545-1551

  Quadri, Syed M ^a   Malik, Atif B ^a   Chu, Hung B ^a   Freedman, Ralph S ^a   Vriesendorp, Huibert M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

biodistribution; human IgM; indium 111; intraperitoneal administration; yttrium 90

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY IN 111; MONOCLONAL ANTIBODY Y 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CANCER MODEL; CARCINOMATOUS PERITONITIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; PERITONEAL NEOPLASMS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0029742459     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Order SE, Klein JL, Leichner PK, Frincke J, Lollo C, Carlo DJ. 90-yttrium antiferritin. a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 1986;12:277-281.
2. 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988;14:1033-1042.
3. Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. Cancer J Clin 1994;44:43-63.
4. Abdel-Nabi H, Doerr RJ. Clinical applications of indium-111-labeled monoclonal antibody imaging in colorectal cancer patients. Semin Nucl Med 1993;23:99-113.
5. Vriesendorp HM, Quadri SM, Williams JP. Radioimmunotherapy. In: Armitage JO, Antman K, eds. High dose cancer therapy. Philadelphia: Williams & Wilkins; 1992:84-123.
6. Leichner PK, Koral KF, Jaszczak RJ, Green AJ, Chen GT, Roeske JC. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 1993;20:569-577.
7. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988;48:3270-3275.
8. Vriesendorp HM, Herpst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991;9:918-928.
9. Hnatowich DJ, Chinol M, Siebecker DA, et al. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. J Nucl Med 1988;29:1428-1434.
10. Herpst JM, Klein JL, Leichner PR, Quadri SM, Vriesendorp HM. Survival of patients with treatment resistant Hodgkin's disease after yttrium-90-antiferritin. J Clin Oncol 1995;13:2394-2400.
11. Dykes PW, Gradwell AR, Chapman CE, Vaughan ATM. Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev 1987;14:87-106.
12. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-885.
13. DeJager R, Abdel-Nabi H, Serafini A, Pecking A, Klein JL, Hanna MG Jr. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med 1993;23:165-179.
14. Sands H, Jones PL. Methods for the study of the metabolism of radiolabeled monoclonal antibodies by liver and tumor. J Nucl Med 1987;28:390-398.
15. Reynolds JC, DelVecchio S, Sakahara H, et al. Antimurine antibody response to mouse monoclonal antibodies: clinical findings and implication. Int J Radiat Appl Inst (B) 1989;16:121-125.
16. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 1987;47:6528-6531.
17. Larson SM, Carrasquillo JA, Colcher DC, et al. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatosis. J Nucl Med 1991;32:1661-1667.
18. Quadri SM, Malik AB, Tang X-Z, Patina R, Freedman RS, Vriesendorp HM. Preclinical analysis of intraperitoneal administration of indium-111 labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 1995;55:5736S-5742S.
19. Greenberg PAC, Kudelka AP, Kavanagh JJ. Ovarian cancer. In: Pazdur R, eds. Medical oncology: a comprehensive review. Huntington, NY: PRR, Inc.; 1993;233-242.
20. Rubin SC. Monoclonal antibodies in the management of ovarian cancer: a clinical perspective. Cancer 1993;71(suppl):1602-1612.
21. Schray MF, Martinez A, Howes AE. Advanced epithelial cancer: salvage whole abdominal radiation for patients with recurrent or persistent disease after combination therapy. J Clin Oncol 1988;6:1433-1439.
22. Reichman B, Markman M, Hakes T. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 1989;7:1327-1332.
23. Julian CG, Inalsingh CH, Burnett LS. Radioactive phosphorus and external radiation as an adjuvant to surgery for ovarian cancer. Obstet Gynecol 1978;52:155-160.
24. Rosenshein NB, Leichner PK, Vogelsang GR. Radiocolloids in the treatment of ovarian cancer, Obstet Gynecol 1979;34:708-720.
25. Crippa F. Radioimmunotherapy of ovarian cancer. Int J Biol Markers 1993;8:187-191.
26. 2 on human epithelial ovarian cancer cell lines. Radiother Oncol 1992;23:150-159.
27. Stewart JSW, Hird V, Dhokia B, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990;8:1941-1950.
28. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403-406.
29. Maraveyas A, Snook D, Hird V, et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994;73:1067-1075.
30. Freedman RS, Ioannides CG, Tomasovic B, et al. Development of a cell surface reacting human monoclonal antibody recognizing ovarian and certain other malignancies. Hybridoma 1991;10:21-33.
31. Chen P-F, Freedman RS, Chernajovsky Y, Platsoucas CD. Amplification of immunoglobulin transcripts by the non-palindromic adaptor polymerase chain reaction (NPA-PCR): nucleotide sequence analysis of two human monoclonal antibodies recognizing two cell surface antigens expressed in ovarian, cervix, breast, colon, and other carcinomas. Hum Antibodies Hybridomas 1994;5:131-142.
32. Lindmo T, Boven E, Cuttitta F, Fedorka J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigens excess. J Immunul Methods 1984;72:77-89.
33. Quadri SM, Mohammadpour H. A convenient synthesis of 2-p-aminobenzyl-3-methyl and 2-p-aminobenzyl-3-benzyl derivatives of diethylenetriaminepentaacetic acid (DTPA): carbon backbone modified bifunctional chelating agents. Bio Med Chem Lett 1992;2:1661-1664.
34. Quadri SM, Vriesendorp HM, Leichner PR, Williams JR. Evaluation of indium-111-and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993;34:938-945.
35. 90Y-labeled B72.3 immu noconjugate (GYK-DTPA) in beagle dogs. Nucl Med Biol 1993;20:559-570.
36. Wang S, Quadri SM, Tang X-Z, et al. Liver toxicity induced by combined external beam irradiation and radioimmunoglobulin therapy. Radiat Res 1995;141:292-302.
37. 32P) in New Zealand white rabbits. Radiology 1980;134:729-734.
38. Mychalczak BR, Fuks Z. The role of radiotherapy in the management of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of ovary. New York, NY: Raven Press; 1993:229-241.
39. Casper ES, Kelsen DP, Alcock NW, Lewis Jr. JL. Intraperitoneal cisplatin in patients with malignant ascites: pharmacokinetics evaluation and comparison with i.v. route. Cancer Treat Rep 1983;67:235-238.